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Abstract
Genomic variation underlying major depressive disorder (MDD) likely involves the interaction and regulation of
multiple genes in a network. Data-driven co-expression network module inference has the potential to account for
variation within regulatory networks, reduce the dimensionality of RNA-Seq data, and detect signiﬁcant geneexpression modules associated with depression severity. We performed an RNA-Seq gene co-expression network
analysis of mRNA data obtained from the peripheral blood mononuclear cells of unmedicated MDD (n = 78) and
healthy control (n = 79) subjects. Across the combined MDD and HC groups, we assigned genes into modules using
hierarchical clustering with a dynamic tree cut method and projected the expression data onto a lower-dimensional
module space by computing the single-sample gene set enrichment score of each module. We tested the singlesample scores of each module for association with levels of depression severity measured by the Montgomery-Åsberg
Depression Scale (MADRS). Independent of MDD status, we identiﬁed 23 gene modules from the co-expression
network. Two modules were signiﬁcantly associated with the MADRS score after multiple comparison adjustment
(adjusted p = 0.009, 0.028 at 0.05 FDR threshold), and one of these modules replicated in a previous RNA-Seq study of
MDD (p = 0.03). The two MADRS-associated modules contain genes previously implicated in mood disorders and
show enrichment of apoptosis and B cell receptor signaling. The genes in these modules show a correlation between
network centrality and univariate association with depression, suggesting that intramodular hub genes are more likely
to be related to MDD compared to other genes in a module.

Introduction
RNA-Seq is a transcriptome proﬁling technique that
uses next-generation sequencing to provide a sensitive,
quantitative measurement of RNA abundance or gene
expression. Challenges associated with the RNA-Seq
approach include both technical limitations (e.g., tissue
heterogeneity and batch effects) and statistical concerns
(e.g., over dispersion and multiple hypothesis testing).
Furthermore, major depressive disorder (MDD) is a
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complex phenotype involving systems of interacting
genes, and single-gene associations of expression have not
reached genome-wide signiﬁcance. While these approaches have provided biological insights and identiﬁed
candidate biomarkers associated with some neurological
diseases1,2, network and gene–gene interaction approaches may enrich the variable space to better predict or
characterize the genomic architecture of more complex
phenotypes3.
Co-expression network techniques for detecting coordinated gene expression changes at a gene set (modular)
level have potential power to provide novel insights into
the genetic architecture of psychiatric disorders4,5. A
module can be understood as a collection of genes that
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Fig. 1 Workﬂow for RNA-Seq computational analyses: Preprocess the raw counts data (Step 1). Obtain normalized RNA-Seq expression values
and perform coefﬁcient of variation ﬁltering (COV threshold = 0.8) (Step 2). Create weighted co-expression matrix and apply hard threshold (0.2) to
construct an un-weighted co-expression network from the topological overlap matrix (Step 3). Detect modules using dynamic tree cut with WGCNA
(Step 4). Steps (3) and (4) are iterated to tune hard threshold (0.2) to yield modules of similar size. Collapse expression of individual genes onto
modules with ssGSEA (Step 5). Perform statistical testing with false discovery adjustment to ﬁnd association between modules and MADRS score
(Step 6). Modules passing the false discovery threshold are tested for replication in an independent study

are highly interconnected (e.g., by co-expression) and,
thus, more likely to share a similar biological function6.
Modular analysis also helps alleviate the multiple
hypothesis testing problem inherent in RNA-Seq data and
may be more robust than single-gene investigation.
Clustering thousands of genes into pathway-sized modules and collapsing these genes onto single statistical units
signiﬁcantly reduces the number of hypotheses to be
tested. Combined with statistical learning methods, as
well as meta-analyses of existing databases, modular
analyses of co-expression networks have been conducted
in several studies to identify groups of differentially
expressed genes in schizophrenia7–9, autistic spectrum
disorder10, Alzheimer’s disease11, and MDD12.
Initial genome-wide association studies (GWAS) of
MDD had limited success at ﬁnding signiﬁcant variants
due to the contribution of many loci with small effect
sizes as well as the heterogeneous characteristics of MDD
and the complex interaction between genetic variation
and environmental factors13. More recently, many small,
but signiﬁcant, main effect loci have been identiﬁed
through the accumulation of extremely large samples14,15.
Similarly, it has been difﬁcult to identify signiﬁcant single-

gene effects at the expression level from RNA-Seq of
MDD. In Mostafavi’s RNA-Seq study of 922 subjects, only
29 genes were found to have signiﬁcant association with
MDD status at the relaxed FDR threshold of 0.25, but sets
of top genes were signiﬁcantly enriched for the IFN α/β
signaling pathway16. Combining a modular approach with
meta-analysis of 11 transcriptome studies of postmortem
brains, Chang et al. identiﬁed a transcriptome module of
88 genes based on consistency with GWAS results for
MDD, other neuropsychiatric disorders, and brain function12. This meta-module is enriched for genes that
encode proteins implicated in neuronal signaling and
structure.
Modularity is a ubiquitous feature of biological systems17 and genes within modules tend to be functionally
related18,19, which may help us ﬁnd regulatory genes that
affect disease risk along with direct disease-related genes.
Thus, in the present study, we applied a data-driven
approach to detect depression gene modules (DGMs),
which are co-expression modules associated with
depression phenotypes. Because our analytical approach is
sensitive to weak individual effects and takes biological
interactions among genes into account, it can potentially
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reveal biological effects that are neglected in univariate
models. Using RNA-Seq from peripheral blood, we constructed a co-expression network for the combined MDD
and healthy control (HC) subjects and created hierarchical clusters of similar size using the dynamic tree cut
from the weighted gene co-expression networks analysis
(WGCNA) tool20. We then projected each subject’s genelevel expression onto a lower-dimensional space of
modules using single-sample gene set enrichment analysis
(ssGSEA) approach21,22.
The resulting 23 modular expression proﬁles were not
conditioned on the phenotype and thus may be used as
predictor variables in a greatly reduced hypothesis space.
We applied false discovery rate adjusted linear regressions
to each modular expression proﬁle to identify modules
that are associated with subject’s depression severity
characterized by the Montgomery-Åsberg Depression
Scale (MADRS). We then explored the relation of several
genes in these signiﬁcant modules to the clinical phenotype, MDD, along with other psychiatric disorders based
on the extant literature. Of the two modular expression
proﬁles that survived multiple hypothesis testing, one
module (DGM-5) replicated in an independent data set.

Methods and materials
The co-expression network module analysis involves
multiple steps to obtain gene set predictors of MDD
(Steps 1–6, Fig. 1). In this section, we provide details of
the RNA-Seq preprocessing of the raw count data, normalization of expression values, and variation ﬁltering
(Steps 1 and 2). We describe our iterative approach to
module construction using a hard threshold of the coexpression matrix and the topological overlap matrix
(Step 3), combined with clustering by the dynamic tree
cut algorithm (Step 4). Steps 3 and 4 are iterated with a
grid of hard thresholds to obtain modules of similar size.
We reduce the hypothesis space by collapsing the
expression of individual genes onto these modules (Step
6) and test these module features for association with
MADRS score with false discovery rate adjustment.
Subjects

Participants between the ages of 18 and 55 years were
recruited from the clinical services of the Laureate Psychiatric Clinic and Hospital (LPCH) and media advertisements in the Tulsa metropolitan area, Oklahoma. A
total of N = 160 subjects, including 80 subjects who met
DSM-IV-TR criteria for MDD (52 females, mean age =
33 ± 11) and 80 HCs who showed no history of any major
psychiatric disorder in a ﬁrst-degree relative (41 females,
mean age = 31 ± 10), participated in the study. However,
because one MDD subject’s expression data were corrupted and two additional subjects (one MDD and one
HC) were outliers, their data were excluded from the
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analyses (see below for details). The diagnosis of MDD
was established using the Structural Clinical Interview for
DSM-IV-TR Axis I Disorders (SCID-I/NP; 1 January
2010) and conﬁrmed by an unstructured interview with a
psychiatrist. Exclusion criteria included the use of psychotropic medications for at least 3 weeks prior to study
entry, major medical or neurological illness, psychosis,
traumatic brain injury, and a history of drug/alcohol abuse
within 1 year. All subjects gave written informed consent
to participate in our study and received ﬁnancial
compensation.
The present study was approved by the Western Institutional Review Board, and it was conducted according to
the principles expressed in Declaration of Helsinki. All
participants gave written informed consent to participate
and received ﬁnancial compensation.
Materials

The
clinician-administered
Montgomery-Åsberg
Depression Rating Scale (MADRS; Williams & Kobak,
2008) was used to rate the severity of depressive symptoms. In clinical trials of major depressive disorder, the
ten-item diagnostic questionnaire MADRS is accepted by
the FDA and other health authorities as valid and reliable
rating instruments for obtaining the primary outcome
measure of antidepressant treatment efﬁcacy23.
Steps 1 and 2. RNA-Seq data generation and processing

Morning blood samples were obtained from the participants, and peripheral blood mononuclear cells (PBMCs)
were isolated using cell preparation tubes. We quantiﬁed
RNA expression obtained from frozen (PBMCs) by analyzing complementary DNA derived from the PBMCs
with RNA-Seq. Following initial quality-control steps,
sequencing libraries were generated using the Illumina
Truseq Stranded mRNA with library prep kit according to
the manufacturer’s protocol. Sequencing was performed
on an Illumina Hiseq 3000 instrument with paired-end
150 bp reads. Samples were sequenced to an average
depth of 30 million reads and RNA integrity number of
8.6 per sample. RNA-Seq measures gene expression by
sequencing, yielding the abundance of each transcript
present. After gene-level transcripts were computed from
transcriptomic sequencing, the sequencing reads are
aligned and mapped to individual exons. We used RefSeq
for the cDNA alignment. The total number of read counts
was obtained per gene from the mRNA expression.
Normalization of the gene counts was performed with
conditional quantile normalization (CQN), which
accounts for differences in library size and also adjusts for
GC content and gene length24. These normalized values
were used for subsequent analyses. The RNA-Seq raw
counts preprocessing steps involved: (i) removal of genes
with low counts (threshold deﬁned below) and
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normalization, (ii) outlier detection, (iii) batch effect
correction, and (iv) high coefﬁcient of variation (COV)
ﬁltering of genes. Brieﬂy, analyses included autosomal
genes with ≥15 individuals with ≥2–7 reads, depending on
the library size. Then, we applied an angle-based outlier
(ABO) detection25 to remove samples with exceptionally
small ABO factor. Batch effect was adjusted with the
function “removeBatchEffect” from the R package
“limma”26 (Fig. S2). Reasoning that expression values that
differ greatly across subjects are likely due to technical
variability27, we excluded genes with (COV) larger than
0.8 to obtain genes whose expression values were roughly
consistent across samples. Details on data generation and
preprocessing are provided in Supplements 1, 2. Preprocessed RNA-Seq data are available upon request to
corresponding authors.
Steps 3 and 4. Gene co-expression network construction
and module identiﬁcation

We used an iterative procedure to identify the module
predictors for association testing with depression severity.
We ﬁrst built a co-expression network by calculating the
correlation of the pairwise gene expression, applied a hard
threshold to the network and then computed the network’s topological overlap matrix (TOM) dissimilarity
between the genes (Fig. 1, Step 3). We used the new TOM
distance matrix from the hard threshold to construct a
hierarchical tree and used dynamic tree cutting to construct modules (Step 4). Steps 3 and 4 (Fig. 1) were
repeated for a grid of hard thresholds to obtain a ﬁnal
hard threshold (0.2) that yields similar module sizes
(mean size of 200 genes28). In the optimal weighted network, we removed edges with correlation values below a
threshold of 0.2. Our motivation was to ﬁnd cluster sizes
that were relatively similar in size and with a large enough
number of genes for ssGSEA to be effective. Gene set
enrichment often tests modules of size 200 genes, and
having similar module sizes (Fig. S3) help alleviate
potential module-size bias in ssGSEA. We note that we
did not detect correlation between module-size and statistical signiﬁcance of ssGSEA module associations with
depression phenotype. We obtained 23 collections of
genes (modules) with similar connectivity in the coexpression network. Slight variation of the hard threshold
value does not have a meaningful effect on the number of
modules.
To perform the hierarchical clustering, we used
unsigned weighted correlation networks analysis20
(WGCNA), which has been used in a variety of ﬁelds (e.g.,
cancer and brain imaging analysis29). Speciﬁcally, we
measured dissimilarity between pairs of expression values,
created a dendrogram of genes, and identiﬁed modules
from the different levels of similarity structure. We used a
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dynamic tree cut clustering method30 to identify modules
from the TOM matrix of this network of normalized gene
expression values. The WGCNA tool includes a dynamic
tree cut method that provides a ﬂexible dendrogram
cutting mechanism that is effective at detecting nested
modules.
Step 5. Projection of module gene sets onto lowerdimensional feature space

We generated normalized enrichment proﬁles for each
gene cluster using single-sample gene set enrichment
analysis (ssGSEA)21,22. Similar to the notion of eigengene
in WGCNA20, ssGSEA calculates an enrichment proﬁle of
modules in each subject based on individual expression
values in the modules. However, instead of using a principal component analysis, ssGSEA is based on the
cumulative distribution of the ranked expression values.
Particularly, ssGSEA assigns a sample-level enrichment
score to a gene module by rank-normalizing the expression values and comparing the empirical cumulative distribution of these ranks inside and outside that module.
The scaled module’s score of a sample represents the
degree to which its genes are coordinately up- or downregulated within that sample. Consequently, within a
particular sample, the expression proﬁle in the higherdimensional space of genes is projected onto a lowerdimensional space of modules, yielding a smaller set of
new variables that helps reduces the hypothesis space’s
dimension and is more biologically interpretable.
One of our goals was to test module hypotheses in an
independent data set. We felt the ssGSEA would provide a
more reproducible mechanism than eigengene for collapsing a set of genes onto a predictor variable. The
ssGSEA method can be applied to an independent
expression data set directly without recomputing a correlation matrix and the eigengenes. Furthermore, we did
not strictly follow the WGCNA protocol to create modules. Rather than optimize a soft threshold power based
on the degree of distribution, we optimized a hard
threshold cutoff based on similar module sizes.
Step 6. Testing gene module features for association with
depression severity

The modules’ enrichment proﬁles were then considered
as explanatory variables in the linear models to estimate
each participant’s scaled MADRS score. In addition to
these enrichment scores, the design matrix also included
sex, age, BMI, and batch as covariates. Further, because
smoking status is known to be associated with depression31 and may confound gene expression32,33, we also
considered an additional model where smoking status is
added as a covariate. Moreover, although the majority of
participants are Caucasian, the data set also contains
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Table 1 Characteristics of the sample
Variable

All (N = 157)

MDD (n = 78)

HC (n = 79)

Age (years)

32 (1)

33 (10)

31 (10)

1.40 (155)

Sex
(Female/male)

t or χ2

2.93
91/66

51/27

40/39

(1)

Caucasian

120

59

61

1.09 (5)

African-American

12

6

6

Native American

4

3

1

SRA

Native Hawaiian/Paciﬁc Islander

2

1

1

Asian American

4

2

2

Other

15

7

8

Employed full time

55

25

30

Employed part time

19

11

8

Homemaker

5

1

4

Full-time student

34

11

23

Occupational status

Unemployed less than 6 months, but expects to work

7

4

3

Unemployed 6 months or more, but expects to work

1

1

0

Unemployed 6 months or more and does not expect to work

1

1

0

Other

2

1

1

Some high school

3

1

2

High school graduate

11

8

3

7.62 (7)

Educational status

Some college/technical school

62

32

30

College graduate

37

12

25

Masters or above

10

2

8

Other

1

0

1

Non-smoker

111

46

65

Smoker

14

10

4

BMI

28.1 (6.43)

29.3 (6.81)

26.9 (5.85)

MADRS

11.7 (11.76)

22.2 (7.99)

1.8 (2.45)

10.39 (5)

Smoking status
4.52* (1)

2.33* (155)
21.49** (150)

Values enclosed in the parenthesis represent standard deviations (under “All,” “MDD,” and “HC”) or degrees of freedom (under “t or χ ”). The variables of SRA,
occupational status, and educational status contained missing values
HC healthy controls, SRA self-reported ancestry, BMI body mass index, MADRS total score on Montgomery-Åsberg Depression Rating Scale
*p < 0.05; **p < 0.01
2

other self-reported ancestries (SRAs). As a sensitivity
analysis, we tested our hypotheses on a subset of the data
with only Caucasian participants to examine whether the
results were confounded by multiple SRAs. The p values
obtained from the analysis are corrected based on
Benjamini–Hochberg’s procedure34. Genes in modules

with false discovery rate (FDR) adjusted p values <0.05
were designated as differentially expressed in aggregate.
We also search for the enriched genes among the genes
within each signiﬁcant module using GeneAnalytics35 and
VarElect36 of the GeneCard Suites (http://www.genecards.
org/) for additional interpretation.
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Network centrality and individual gene’s importance in
discriminating phenotypes

In a secondary univariate analysis, we investigated the
individual effect of genes by conducting logistic regressions of the diagnosis phenotype (MDD/HC) on each of
the 5912 genes and adjusting the p values according to the
Benjamini–Hochberg procedure34. We also computed
eigenvector centrality for each of the 5912 genes based on
the co-expression network. Centrality analysis approximates the relative importance of genes based on their
connectivity within the network structure: a gene with
higher centrality is more inﬂuential than a low-centrality
gene. The simplest centrality metric is degree centrality,
which counts the number of connections a speciﬁc gene
has with other genes. In this analysis, we computed the
eigenvector centrality, a variant of degree centrality that
takes into account the importance of neighboring genes.
Within the most signiﬁcant modules, we then examined
the relationship between each gene’s centrality and its
individual importance, measured as the negative log of its
adjusted p value:
si ¼  logðpi Þ
We ﬁnd that the centralities of genes within statistically
signiﬁcant modules are more correlated with their univariate diagnosis statistical association compared to genes
in other modules.

Results
According to Chi-square test or t-test, there was no
difference in age, sex, SRA, occupational status, and
educational status between the MDD and HC groups
(Table 1). The MDD group showed signiﬁcantly higher
BMI and, as expected, more severe depressive symptoms
(based on MADRS score) than the HC group. Therefore,
even though BMI does not signiﬁcantly correlate with
MADRS (p = 0.123), we controlled for BMI in our subsequent analyses to ensure our results were not confounded by BMI.
Figure 1 shows the overall workﬂow for RNA-Seq data
analyses. Out of 19,968 identiﬁed genes 12,049 genes with
a low count were removed. The remaining 7919 signiﬁcant counts are then normalized and used as inputs to
the angle-based outlier (ABO) analysis, an outlier detection method that is robust for high-dimensional data
(Supplement 2-ii). We also removed two outlier samples
(one MDD and one HC) with distinctly small ABO factors
(<0.001, Fig. S1). We note that, if included in the analyses,
these two samples would have had exceptionally high
TMM normalization factors. In addition, 2007 expression
values with high variability (calculated by coefﬁcient of
variation) were also ﬁltered out. As a result, input to the
gene co-expression network construction is a logCPM
matrix of dimension 157 samples × 5912 genes. We note
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that the size of this ﬁltered data set is similar to that of
other gene expression studies8,28,37. Our iterative thresholding and dynamic branch cut of the co-expression
network (Steps 3 and 4, Fig. 1) results in 23 modules. The
number of genes in each module ranges from 86 to 746
genes.
After correcting for multiple hypothesis testing, we ﬁnd
that two modules’ enrichment proﬁles, DGM-17 (β =
15.4, se = 4.21, praw = 0.000352) and DGM-5 (β = -5.31,
se = 1.75, praw = 0.00284), are signiﬁcantly associated with
MADRS score (Fig. S4). When tested on only 120 samples
of Caucasian subjects, despite the reduction in power,
these two modules remain signiﬁcantly associated with
this measure of depression severity (praw = 0.0024 and
0.0032). We concluded that the results were robust to
SRA. Furthermore, when smoking status was added as a
covariate in the linear model, DGM-17 (praw = 0.000395)
and DGM-5 (praw = 0.00244) still showed statistically
signiﬁcant associations with MADRS. The results are
similar likely because no participants in the data set were
heavy smokers. However, because the Bayesian Information Criterion of this model is larger than that of the
original model, we presented the result from the original
model without smoking status.
DGM-17 and DGM-5 contain 109 and 291 genes,
respectively, including VRK2, OPRM1, and TCF7L2 in
DGM-17; AKT1, CREB1, CALB1, FAS, FKBP4, FOXP3,
HDAC5, and PDE6C in DGM-5, which, as we discuss
below, are components of pathways potentially related to
mood disorders. Comparing this approach to the traditional individual signiﬁcance of genes on diagnosis phenotypes, we found DGM-17 and DGM-5 contain
signiﬁcantly more top genes compared to other modules
(hypergeometric test results of observing xi genes from
module i in the most 100 signiﬁcant genes are shown in
Table S2). Moreover, within these two signiﬁcant modules, genes’ global centralities are positively correlated
with its statistical association with diagnostic status (Fig.
2). This high correlation between univariate gene signiﬁcance and network centrality implies that genes with
high centrality in DGM-17 and DGM-5 tend to be highly
correlated with diagnosis status.
Replication in previous RNA-Seq study of MDD

We used the RNA-Seq study by Mostafavi et al.16 as a
replication set to test for association with MDD of the
signiﬁcant modules, DGM-17 and DGM-5, from our
current study. This independent data set consists of RNASeq measurements of 15,231 genes in 463 MDD cases and
452 controls. Of the 291 genes in module DGM-5 and 109
genes in module DGM-17 (Supplements 6, 7), we found
238 and 72 genes in Mostafavi’s study that belong to these
two modules, respectively. We applied ssGSEA on these
genes to obtain the enrichment scores of 915 subjects for
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Importance Score vs. Centrality of Individual Genes per Module
17

5
MCM3AP-AS1

FAM13A

PP7080
NR2C2

OXR1
PSMD5

3

0.05 FDR

0.05 FDR
MBNL1-AS1

-Log(adjusted P-value)

USP34

CEBPZ

0.1 FDR

ATP1A1-AS1
FAMMM1P8MIR3661
149B MASP2
TCF7L1
GZF1
SLC13A4
PGM3
EZR-AS1
TAC4
TXLNA
COA5
SENCR
BMP8A LHX4
RHOQ HEXIM1
SLC25A25
UGDH-AS1
POLR2J4
TMEM221
VPRBP
AQP11
TMEM217
RAB11B-AS1
C17orf53 CALB1
COX20
LENG9
PCGF3
Z
MNCFT5P416
FTSJ3
MYO19
GNPTG
DNAJC9-AS1
FXR2CAMK1
SPRN
RUSC1
RAD17
PDE6C
AMPH
CNTRL
GOLGA8HLCA5L
ATAD5
GPM6B
C2orf88
AKAP5
ZNF814
RNF39
LRRC37A2 OSGEPL1
CERS5
CACNB2
FOXP3
ZNF83 M
NT
C5CC2
PCP4L1
MROH6
ATG14
ALG12 CD160
KDELR3
RUFY3
CUL4A
UBE2E1
CLEC2B
RPUSD3
WARS2
ZNHIT3
RBM4B
ZNF506
ZNF865
FKBP4
ATP2C2
HSPD1UTP14A
DPP7
ZNF878
TUBB1
UTP20
TFIP11
JAM3
DHODH
FOCADGALNT10
ZNF552
VN1R1
FAM160B2
RNF149STX17COL4A4
SNX21
ZFP69
ARHGEF26
C9orf169
PROX2
SPDYE5
SEC13
SIGLEC16
PDHX
CCT6P3
ZNF57 C6orf136
RPRD1A
LGALS8
ZSWIM7
TMEM131
NREP
CRLF3
LRRC37A6P
HDAC5
REV3L
KMT2C
DCDC2B
FOXM1
DNAJC17
HSPB9 PTPN14
C11orf80
SLC48A1
NDUFAF2
CFD
THADA
EVA1C
WIPI1
ALOX12
PSMD7
DNAH1
UBTF
GPR155ITIH2
EGLN1 MSL1
ZNF407
PPM1N TAF3 HLA-J
SPAG4
PARD6G PXK
FAM86HP
TACC1
DDX56
DRG1
DOT1L
GTF2F1
NFE2L3
NUDT13
LYG2
LARS
S100A1
TTPAL
MARCH1
FAM98B
A2MP1
BSN
CCDC181
PPWD1
TNK1 HECTD1
EFR3B
GPR137
C1orf146
KRTAP5-1
MIR635
TSC1 CD48
CLASRP
MYO5B
GSTO1
TMPRSS9
NFYC
UHRF1
GSE1
C11orf42
FAS
RNF139-AS1
PLEKHB1
BCS1L
SBF1 GNB4
INTS4L2
ZNF805
NUDT5
MRS2
TRAF1
C19orf68 GRTP1 ERCC6L
ZC3H8
TP53I3
SENP1
CD72
TRIM7AKT1
CARD14
ANXA6
MLLT10P1
ENTPD3
HACL1
ZNF646
TM6SF1
B9D2
BTBD2
ATP5H
PIGZ
AFAP1-AS1
TMEM263
SLC26A2
RNF113A
JPX RNF224
GUCY1B2
ICMT
GINS3
DCLRE1C
MSTO1
TMEM259
GALNS
ALS2CR12
PPARA
LRP11
SNRPD2
SAFB
HEXA-AS1 PRPF38A
METTL25
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the two modules. Because MADRS score is not reported
in this independent data set, we alternatively ran a logistic
regression of the diagnosis phenotype (MDD/HC) on the
module’s enrichment score, including sex, age, and BMI
as in the original modular regression. Even though we
only found 82% overlap of module DGM-5’s genes with
the Mostafavi data set, DGM-5’s enrichment score was
shown to be signiﬁcantly associated with the diagnosis
status in this independent data set (p value = 0.033). We
found no signiﬁcant association of DGM-17’s enrichment
value with the diagnosis phenotype in the replication set.
However, this may be explained by the fact that more than
a quarter of the genes in the original, already relatively
small, module DGM-17 are not present in the replication
data set due to the difference in low-abundance ﬁltering
thresholds.

Discussion
We employed a novel combination of approaches to
RNA-Seq data obtained from a cohort of depressed and
healthy individuals that led to the replication of a
depression gene module in a two-stage analysis. Some of
these approaches include enforcing similar module sizes

to guide co-expression network thresholding and gene set
variation analysis to collapse genes onto modular units of
analysis to reduce multiple hypothesis testing. Most gene
expression studies have used individual genes as the unit
of analysis for differential expression between phenotypes.
Module-based analysis is a sensitive technique to detect
weak, but coordinated, gene expression changes at a
module level. A related limitation of this approach is that
summarizing the score for a module to one value, whether
by ssGSEA, eigengene or other dimension reduction
techniques, results in the loss of information at the single
gene level. However, this technique reduces the high
dimensionality of the hypothesis space by clustering
thousands of genes into a manageable number of modules
of interacting genes that may share similar biological
functions. In the lower-dimensional variable space, statistical learning methods can be applied to identify gene
modules that are signiﬁcantly associated with depression
severity without overﬁtting. Thus, we argue that a genemodule approach based on expression networks is a
useful statistical model of the genetic architecture of
complex diseases such as depression, in which multiple
interacting homeostatic systems are affected38.
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The two statistically signiﬁcant modules (after FDR
adjustment) contain candidate genes for MDD and related
disorders. Several genes in module DGM-5 include
HDAC5 and CREB1 whose expression has been reported
to be altered in MDD patients39. The histone methylation
processes in which HDAC5 participates have also been
implicated across different psychiatric disorders40. Linkage of variation in CREB1, the cyclic AMP response
element-binding protein gene, to anger expression and
treatment outcome in MDD patients41,42 as well as
gender-speciﬁc susceptibility for MDD43,44 has been
reported. CREB1 is also considered one of the important
targets of antidepressants45. FOXP3, an intracellular
marker for regulatory T cells (Tregs), has shown
decreased expression level in depressed patients compare
to HC group46, while our group previously reported
increased circulating numbers of Tregs in MDD versus
HC47. FOXP3 also plays an essential role in maintaining
homeostasis of the immune system, one of the pathways
that have signiﬁcant association with aggregate psychiatric
disorders40. Variation in FAS, a gene involved in T cell
activation and apoptosis, is associated with antidepressant
prognosis48. A signiﬁcant increase in FAS expression is
also observed in depressed patients49.
Another noteworthy gene in module DGM-17 is
OPRM1 because of its association with depression
symptoms through interaction with stressful life events50.
Alteration of opioid neurotransmission has also been
observed in MDD patients51. Additional gene-level
information in the signiﬁcant modules, DGM-5 and
DGM-17, is summarized in Table 2 based on relevance to
mood disorders from the literature. We found more mood
disorder-related genes in the literature for DGM-5 than
DGM-17, which may explain the fact that DGM-5 replicated while DGM-17 did not. However, we acknowledge
that many of the genes found in the mood disorder literature have not been well replicated because, in part,
MDD is a complex disorder of heterogeneous etiology.
This complexity is a potential motivation for modular
approaches that accumulate the coordinated variation of
genes to detect gene modules related to depression.
Module DGM-5 also contains more genes than DGM-17;
however, we did not ﬁnd evidence of module-size bias,
ﬁnding no correlation between module size and statistical
signiﬁcance of modules (results not shown). Another
reason that DGM-17 did not replicate may be due to the
lower overlap of genes in the replication data set (83% for
DGM-5 vs 73% for DGM-17).
In addition to containing several candidate genes,
DGM-5 and DGM-17 show enrichment (q value 0.2) for
several pathways involving immune function (Table 3).
The enrichment of the apoptosis pathway in DGM-5
suggests a genetic signature involving brain regionspeciﬁc volume reduction due to cell loss in MDD52,53.

Page 8 of 12

The enriched PI3K/AKT activation pathway is involved in
apoptosis and plays a role in mRNA translation of type I
interferon-dependent genes54. The viral protein R (VPR)
pathway, enriched in DGM-17, is involved in the induction of apoptosis in proliferating cells and B cell signaling.
The DMG-5 module contains the binding protein for VPR
(VPRBP in Supplement 7), which suggests additional
overlap of the function of these two modules.
The apoptosis signal in the blood expression may originate from the brain (e.g., neuronal death due to apoptosis) and/or from other sources of cellular stress (e.g.,
activated T cells). The detection of the apoptosis signal in
DGM-5 suggests the signal may be brain derived. One
may strengthen the evidence for brain-derived apoptosis
by testing for the association of expression of apoptosis
genes with brain volumetric variation. This hypothesis
could be tested in a whole-brain approach or a more
targeted region-of-interest approach, conditioning on
MDD status, and adjusting for age.
As a secondary analysis, we compared the co-expression
network centrality of each gene with the statistical signiﬁcance of its univariate effect on MDD status. Within
the most signiﬁcant modules, we found a positive correlation between a gene’s centrality and the statistical signiﬁcance of the gene’s differential expression. In other
words, “hub” genes in these top modules are potentially
more predictive of the diagnosis phenotype compared to
other genes that have lower centrality in the modules. In
addition to the cumulative variation of genes within
modules, using information related to the centrality of
genes may improve the discovery of MDD-related genes
and further limit the number of hypothesis tests. Hub
genes in signiﬁcant modules also may make it easier to
identify biologically meaningful genes55.
One of the limitations of our study is the relatively small
sample size. However, the dimensionality reduction,
multiple test adjustment, and replication in a previous
RNA-Seq MDD study adds evidence that module DGM-5
is not an artifact. A recent microarray study56 did not
replicate individual gene effects found in the Mostafavi
RNA-Seq study. However, their meta-analysis of the
p values identiﬁed six genes that showed a consistent
effect (the genes had p < 0.05 in both studies)56. Similarly,
Leday et al.57 used a Bayesian technique to identify concordant gene effects across two independent cohorts.
DGM-5, in the current study, contains many genes that
are biologically relevant or previously associated with
mood disorders (Table 2). However, the pathway enrichment signals of DGM-5, such as apoptosis, point to genes
outside of Table 2 as playing an important role in MDD
etiology. Incorporating eQTL analysis may ﬁll in part of
the functional gaps in the DGM-5 network and further
characterize the mechanisms of this mood disorder
module.
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Table 2 Mood disorder-related genes in signiﬁcant modules and summary of their relevance to mood disorders from
the literature
Module Gene

Description/related pathways

Prior studies linkage to mood disorder/
schizophrenia

DGM-17 OPRM1 μ-opioid receptor/GABAergic synapse

Stressful life events50
Sustained sadness condition in women51
Response to antidepressants65

DGM-5

HDAC5

MDD pathophysiology39

Histone deacetylase 5/ phospholipase-C Pathway

Histone pathways66
DGM-5

CREB1

The cyclic AMP response element-binding protein 1, sequence-speciﬁc DNA

MDD pathophysiology39

binding and enzyme binding/constitutive signaling by AKT1 E17K in cancer

Anger expression and treatment outcome in
MDD patients41,42
Gender-speciﬁc susceptibility for MDD43,44
Important targets of antidepressants45

DGM-5

FOXP3

forkhead box P3, the marker for regulatory T cells/Th2 differentiation pathway

Decreased expression level in depressed
patients46
Immune system responses40

DGM-5

FAS

fas cell surface death receptor, T-cell activation and apoptosis/ bacterial infections Antidepressant prognosis48
Expression increase in depressed patients49
in CF airways, allograft rejection

DGM-5

FKBP4

FK506 Binding Protein 4, paralog of FKBP5/ PEDF induced signaling, HSF1-

FKBP5: strong evidence for association with

dependent transactivation

MDD67–72

DGM-5

AKT1

AKT serine/threonine kinase 1, critical mediator of growth factor-induced neuronal Schizophrenia73–75
survival/ ICos-ICosL pathway in T-helper cell, development IGF-1 receptor signaling Depression in different populations76
Neuronal pathways66

DGM-17 VRK2

Vaccinia related Kinase 2/nuclear envelope reassembly, mitotic prophase.

Schizophrenia77–79

DGM-17 TCF7L2

Transcription Factor 7 Like 2/Wnt signaling pathway

Schizophrenia80
Genetic variants that are crucial in MDD
susceptibility81

Table 3 Reactome pathway enrichment results of the two statistically signiﬁcant MDD modules DGM-5 (replicated) and
DGM-17
REACTOME pathways

Genes in pathway

p value

FDR q value

Over lapping genes

148

1.19e−3

0.108

AKT1, BAD, PSMD5, PSMD7, FAS

DGM-5: 291 genes
Apoptosis
Downstream signaling by B cell receptor

97

5.76e−4

0.108

AKT1, BAD, CREB1, PSMD5, PSMD7

PIP3/AKT and PI3K/AKT signaling activation

29

4.82e−4

0.108

AKT1, BAD, CREB1

GAB1 signalosome

38

1.07e−3

0.108

AKT1, BAD, CREB1

PI3K events in ERBB4 and ERBB2 signaling

38

1.07e−3

0.108

AKT1, BAD, CREB1

tRNA aminoacylation

42

1.44e−3

0.108

WARS2, DARS2, LARS

AKT phosphorylates targets in the cytosol

12

1.77e−3

0.108

AKT1, BAD

33

2.38e−5

0.016

NUP214, SLC25A5, PSIP1

DGM-17: 109 genes
Interactions of Vpr with host cellular proteins

Comprehensive results of the pathway enrichment analysis for all modules are presented in Table S1. The Reactome enrichment FDR q value threshold for DGM-5 and
DGM-17 is 0.2
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In the ﬁrst stage of our analysis, we used MADRS as the
primary outcome with the aim of including greater phenotypic variation than the diagnostic phenotype. Using a
precision quantitative trait in a population has the
advantage of capturing more variation than a
case–control phenotype and may also have more power.
For example, it has been shown that dichotomizing a trait
variable at the median reduces the power by the same
amount as throwing away 1/3 of the data58. One limitation of treating MADRS quantitatively is the lack of variation in the scale among healthy subjects. In the second
stage analysis, we used diagnostic status as the dependent
variable because depression severity was not available.
Another potential limitation of our study is the use of
gene expression from PBMCs, which contain many cell
types and may not detect brain-speciﬁc mechanisms16,56.
Peripheral blood is an easily accessible source of cells that
may more easily translate into a clinical biomarker compared to cell or tissue-speciﬁc gene expression. We did
not ﬁnd signiﬁcant overlap between our top module genes
and known cell-type signatures; however, depressionassociated changes in cell frequencies may account for
some of the differences in gene expression59. While effect
sizes may be diluted if small subsets of cells contribute to
the signal, we were able to detect module-level signals that
replicated in an independent study. Deconvolution
methods may help identify cell-speciﬁc differences in
major immune system cells (such as monocytes, Thelper,
B and NK cells) and uncover cell-speciﬁc gene expression
changes associated with mood disorder phenotypes60.
Our modular approach aggregates the effects of genes
with shared variation to discover depression gene modules. This approach is inﬂuenced by GWAS studies
showing that individual variants with small effect sizes,
dispersed throughout the genome, drive complex disease
risk by key genes and regulatory pathways61. Methods for
aggregating genetic variation and association signals from
prior biological knowledge have been used in GWAS to
facilitate more powerful analysis62,63. At the level of gene
expression, we aggregate the variation from co-expressed
genes into modules. This aggregation was done without
prior pathway knowledge and in an unbiased way (not
conditioned on the phenotype) to mitigate multiple
hypothesis testing. Future studies to reﬁne and characterize these depression-related modules will involve
identifying regulatory variants through cis- and transeQTL and interaction QTL analysis64.
Code availability

https://github.com/insilico/DepressionGeneModules
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